Global QuantiFERON-TB Gold Test Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Global QuantiFERON-TB Gold Test Market Segmentation, By Brand (QFT-Plus (QuantiFERON-TB Gold Plus), and Others), Test Type (Tuberculin Skin Test (TST), and Interferon Gamma Release Assay (IGRA)), Application (People Living with HIV (PLHIV), and Household Contacts with Pulmonary TB), End-User (Diagnostic Laboratories, Hospitals/Clinics and Academic & Research Institutions) - Industry Trends and Forecast to 2032

QuantiFERON-TB Gold Test Market Size

• The global QuantiFERON-TB Gold test market size was valued at USD 679.48 million in 2024 and is expected to reach USD 1,239.15 million by 2032, at a CAGR of 7.8% during the forecast period
• This growth is driven by factors such as the global tb burden and high-risk populations, technological advancements in diagnostics and rising awareness and screening programs

QuantiFERON-TB Gold Test Market Analysis

• QuantiFERON-TB Gold test devices are essential diagnostic tools used for detecting latent tuberculosis (TB) infections by measuring the release of interferon-gamma in response to TB-specific antigens. These tests are widely used in clinical practice to identify asymptomatic TB carriers, allowing for early intervention and prevention of active TB transmission
• The demand for these tests is significantly driven by the global rise in TB cases, increasing awareness of latent TB, and the push for TB elimination by organizations such as the WHO. Technological advancements in interferon-gamma release assays (IGRAs), including improved sensitivity and specificity, further support market growth. The shift towards precision diagnostics and increasing public health initiatives also contribute to the expanding market
• North America is expected to dominate the QuantiFERON-TB Gold test market with 45.6% market share, driven by advanced healthcare infrastructure, widespread adoption of cutting-edge medical technologies, and the strong presence of key market players
• Asia-Pacific is expected to be the fastest growing region in the QuantiFERON-TB Gold test market, with 25.1% market share, driven by rapid healthcare infrastructure expansion, rising awareness about neurological disorders, and increasing healthcare spending
• Interferon Gamma Release Assay (IGRA) segment is expected to dominate the QuantiFERON-TB Gold test market, holding 41.87% market share. IGRAs, including the QuantiFERON-TB Gold Plus, are the most widely used TB diagnostic tests due to their superior specificity and sensitivity compared to traditional Tuberculin Skin Tests (TST), particularly in individuals vaccinated with Bacille Calmette-Guérin (BCG)

Report Scope and QuantiFERON-TB Gold Test Market Segmentation

QuantiFERON-TB Gold Test Market Trends

“Technological Advancements in QuantiFERON-TB Gold Test Devices”

• One prominent trend in the QuantiFERON-TB Gold test market is the rapid advancement of diagnostic technologies, including high-sensitivity assays, automated laboratory systems, and digital integration for seamless data management
• These innovations enhance diagnostic accuracy by reducing false positives, enabling early detection of latent TB infections, and providing rapid, reliable results. This improves patient outcomes and supports large-scale TB control efforts in both high- and low-burden settings 

  • For instance, next-generation QuantiFERON-TB Gold Plus assays incorporate dual-antigen detection, targeting both CD4 and CD8 T-cell responses, which improves test sensitivity and specificity, particularly in immunocompromised patients

• These advancements are transforming the global TB diagnostics landscape, driving demand for cutting-edge QuantiFERON-TB Gold test solutions that offer superior accuracy, faster turnaround times, and streamlined laboratory workflows. This trend is further supported by the integration of artificial intelligence (AI) for automated data analysis, remote monitoring, and enhanced clinical decision-making

QuantiFERON-TB Gold Test Market Dynamics

Driver

“Growing Demand for QuantiFERON-TB Gold Test Due to Rising Global TB Burden”

• The increasing global prevalence of latent tuberculosis (TB) infections, coupled with the push for TB eradication, is significantly driving the demand for QuantiFERON-TB Gold test solutions 
• With approximately one-quarter of the world's population infected with latent TB, the risk of progression to active disease remains a major public health concern, particularly in high-burden regions
• As more healthcare systems prioritize early TB detection and prevention, the demand for advanced QuantiFERON-TB Gold test assays is expected to rise, improving patient outcomes and reducing the spread of the disease

For instance,

• In 2024, the World Health Organization (WHO) emphasized the importance of latent TB testing in achieving the End TB Strategy's goal of reducing TB incidence by 90% and TB deaths by 95% by 2035. This renewed focus on preventive testing is creating significant growth opportunities for QuantiFERON-TB Gold test manufacturers 
• As a result, the rising global TB burden is driving the need for innovative diagnostic solutions to support early detection and targeted intervention, significantly expanding the market for QuantiFERON-TB Gold test assays

Opportunity

“Integration of Digital Health and AI in QuantiFERON-TB Gold Testing”

• Digital health platforms and AI-powered diagnostics can enhance the efficiency and accuracy of QuantiFERON-TB Gold test systems, improving patient outcomes and optimizing laboratory workflows
• AI algorithms can analyze large volumes of patient data, identify at-risk populations, and predict disease progression, supporting more proactive and personalized TB management
• In addition, AI integration can streamline test interpretation, reduce diagnostic errors, and provide real-time decision support for clinicians, enhancing overall care quality

For instance,

• In March 2025, a study published in the Journal of Clinical Microbiology highlighted the potential of AI-powered TB diagnostics to reduce false-negative rates and improve latent TB detection in immunocompromised patients, demonstrating significant improvements in test accuracy and patient outcomes 
• The integration of AI in QuantiFERON-TB Gold test systems has the potential to revolutionize TB diagnostics, reduce healthcare costs, and expand the reach of advanced TB testing solutions to a broader patient population

Restraint/Challenge

“High Device Costs and Complex Reimbursement Pathways”

• The high cost of QuantiFERON-TB Gold tests remains a significant barrier to market growth, particularly in low- and middle-income countries where TB is most prevalent.
• These tests, which require specialized laboratory equipment and trained personnel, can be significantly more expensive than traditional tuberculin skin tests, creating financial challenges for healthcare providers and patients.
• In addition, the need for sophisticated infrastructure and cold chain logistics can further limit the adoption of these tests in resource-limited settings

For instance,

• In February 2025, an article published by Global Market Insights highlighted that the high initial costs and ongoing maintenance expenses associated with QuantiFERON-TB Gold tests, coupled with limited reimbursement coverage, remain major barriers to widespread adoption, particularly in emerging markets 
• As a result, these financial and logistical challenges can limit the accessibility of QuantiFERON-TB Gold test assays, reducing their overall impact on patient care and market growth

QuantiFERON-TB Gold Test Market Scope

The market is segmented on the basis of brand, test type, application and end user.

In 2025, the Interferon Gamma Release Assay (IGRA) is projected to dominate the market with a largest share in test type segment

The Interferon Gamma Release Assay (IGRA) segment is expected to dominate the QuantiFERON-TB Gold test market, holding the largest share of approximately 41.87% as of 2025. IGRAs, including the QuantiFERON-TB Gold Plus, are the most widely used TB diagnostic tests due to their superior specificity and sensitivity compared to traditional Tuberculin Skin Tests (TST), particularly in individuals vaccinated with Bacille Calmette-Guérin (BCG).

The people living with HIV is expected to account for the largest share during the forecast period in application market

In 2025, the people living with HIV (PLHIV) segment is expected to dominate the QuantiFERON-TB Gold test market, holding the largest market share. This is primarily due to the increased susceptibility of individuals with HIV to progress from latent to active tuberculosis (TB) due to their compromised immune systems.

Quantiferon-TB Gold Test Market Regional Analysis

“North America Holds the Largest Share in the QuantiFERON-TB Gold Test Market”

• North America dominates the QuantiFERON-TB Gold test market, accounting for 45.6% of the global market share. This dominance is driven by advanced healthcare infrastructure, widespread adoption of cutting-edge medical technologies, and the strong presence of key market players
• U.S. accounts for around 41.2% of the global market share, primarily due to the high prevalence of chronic pain, Parkinson's disease, and epilepsy, as well as a well-established reimbursement framework that supports the widespread adoption of QuantiFERON-TB Gold test devices
• In addition, the U.S. leads in technological advancements, including the development of closed-loop systems and AI-powered QuantiFERON-TB Gold Test devices, further strengthening the market 
• The availability of comprehensive insurance coverage, robust R&D investments, and a strong focus on patient-centric therapies are also key factors driving market growth in this region

“Asia-Pacific is Projected to Register the Highest CAGR in the QuantiFERON-TB Gold Test Market”

• Asia-Pacific is expected to witness the highest growth rate in the QuantiFERON-TB Gold test market, accounting for approximately 25.1% of the global market share, driven by rapid healthcare infrastructure expansion, rising awareness about neurological disorders, and increasing healthcare spending
• Countries such as China, India, and Japan are emerging as key markets due to their large aging populations and growing burden of chronic neurological conditions such as stroke, Parkinson's disease, and chronic pain
• Japan, known for its advanced medical technology, remains a crucial market for QuantiFERON-TB Gold test devices, with high adoption rates for deep brain stimulation (DBS) and spinal cord stimulation (SCS) technologies. The country continues to lead in the deployment of innovative neurological treatment solutions to enhance patient outcomes
• India is projected to register the highest CAGR in the region, driven by expanding healthcare infrastructure, increasing patient awareness, and a rising demand for advanced pain management therapies

QuantiFERON-TB Gold Test Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

The Major Market Leaders Operating in the Market Are:

• Qiagen (Germany)
• Thermo Fisher Scientific Inc. (U.S.)
• Abbott (U.S.)
• BD (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Hologic, Inc. (U.S.)
• Meridian Bioscience, Inc. (U.S.)
• QuidelOrtho Corporation (U.S.)
• Bio-Rad Laboratories Inc. (U.S.)
• Laboratory Corporation of America Holdings (U.S.)
• Aster Clinical Lab LLP (India)
• DiaSorin S.p.A. (Italy)
• Portea Medical (India)
• SSI DIAGNOSTICA (Denmark)

Latest Developments in Global QuantiFERON-TB Gold Test Market

• In March 2025, QIAGEN filed a lawsuit against bioMérieux in the German Unified Patent Court to protect its QuantiFERON intellectual property. This legal action underscores QIAGEN's commitment to safeguarding innovations in latent tuberculosis (TB) testing, particularly the QuantiFERON-TB Gold Plus assay, which is pivotal in global TB control efforts
• In October 2024, QIAGEN hosted the Global TB Summit, bringing together over 35 experts to discuss advancements in TB diagnostics and treatment strategies. The summit highlighted the critical role of QuantiFERON-TB Gold Plus in detecting latent TB infections and emphasized the need for renewed global efforts to combat tuberculosis
• In June 2024, the American Academy of Pediatrics updated its guidelines to recommend QuantiFERON-TB Gold Plus for screening at-risk children of all ages for latent tuberculosis infection. This endorsement reflects the test's accuracy and reliability, even in infants and children under 2 years old, and aligns with broader U.S. tuberculosis control strategies
• In February 2024, Clinical Pathology Laboratories (CPL) implemented single-tube collection for QuantiFERON TB Gold Plus testing, effective June 10, 2024. This change streamlines the testing process, enhancing efficiency and patient comfort while maintaining the assay's diagnostic accuracy

SKU-74029